Profile data is unavailable for this security.
About the company
Orion Oyj, previously Orion Corporation, is a Finland-based company active within the pharmaceutical industry. The Company is engaged in the research and development, manufacture and marketing of human and veterinary pharmaceuticals and active pharmaceutical ingredients. The core therapy areas of the Company's pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory diseases.
- Revenue in EUR (TTM)1.22bn
- Net income in EUR216.80m
- Incorporated2006
- Employees3.70k
- LocationOrion OyjOrionintie 1AESPOO 02200FinlandFIN
- Phone+358 104261
- Fax+358 104264435
- Websitehttps://www.orion.fi/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AddLife AB | 837.03m | 6.75m | 1.03bn | 2.29k | 158.26 | 2.42 | 11.88 | 1.23 | 0.6483 | 0.6483 | 80.41 | 42.38 | 0.7393 | 3.62 | 5.53 | 4,258,149.00 | 0.6112 | 5.31 | 0.9299 | 8.83 | 37.16 | 36.89 | 0.8267 | 5.79 | 0.4778 | 1.48 | 0.5173 | 31.73 | 6.62 | 31.30 | -60.42 | 8.00 | 44.43 | -1.89 |
| BioArctic AB | 52.62m | 19.58m | 1.23bn | 88.00 | 75.60 | 16.46 | 57.99 | 23.32 | 2.58 | 2.58 | 6.97 | 11.85 | 0.6026 | -- | -- | 6,999,943.00 | 22.43 | 2.24 | 24.80 | 2.56 | 91.73 | 86.52 | 37.22 | 9.76 | -- | -- | 0.0047 | 0.00 | 169.83 | -2.91 | 2,150.71 | -9.69 | 11.83 | -- |
| Bonesupport Holding AB | 56.02m | 22.77m | 1.27bn | 121.00 | 55.87 | 26.24 | 53.60 | 22.65 | 4.05 | 4.05 | 9.96 | 8.61 | 1.19 | 0.657 | 6.36 | 6,245,276.00 | 48.22 | -9.08 | 61.41 | -11.28 | 92.01 | 90.25 | 40.65 | -11.65 | 2.42 | -- | 0.0282 | -- | 79.76 | 43.65 | 459.44 | -- | 18.39 | -- |
| Bavarian Nordic A/S | 947.04m | 197.82m | 1.60bn | 1.38k | 7.83 | 1.15 | 5.87 | 1.69 | 19.46 | 19.46 | 92.83 | 132.47 | 0.5281 | 1.92 | 6.10 | 5,121,349.00 | 11.03 | 1.21 | 13.62 | 1.48 | 65.18 | 53.72 | 20.89 | 4.06 | 1.35 | -- | 0.0139 | 0.00 | 124.14 | 69.78 | 524.66 | -- | 35.76 | -- |
| Vitrolife AB | 298.92m | -327.71m | 1.92bn | 1.13k | -- | 1.70 | -- | 6.44 | -28.33 | -28.33 | 25.84 | 97.73 | 0.1859 | 3.76 | 6.54 | 3,242,818.00 | -20.38 | -4.57 | -21.03 | -4.78 | 56.39 | 58.38 | -109.60 | -21.89 | 2.98 | -30.31 | 0.1353 | -- | 8.60 | 24.99 | -1,077.41 | -- | -7.95 | 3.30 |
| Camurus AB | 146.67m | 36.86m | 2.45bn | 213.00 | 66.47 | 18.56 | 64.45 | 16.72 | 7.49 | 7.49 | 30.11 | 26.84 | 1.07 | 1.17 | 7.29 | 8,060,329.00 | 26.85 | -1.13 | 33.67 | -1.41 | 92.87 | 90.05 | 25.13 | -1.63 | 4.13 | -- | 0.0162 | -- | 79.52 | 103.39 | 676.63 | -- | 16.29 | -- |
| ALK-Abello A/S | 646.88m | 65.17m | 3.56bn | 2.82k | 62.71 | 6.53 | 34.20 | 5.51 | 2.09 | 2.09 | 20.90 | 20.10 | 0.7402 | 1.32 | 6.11 | 1,708,215.00 | 7.46 | 3.50 | 9.42 | 4.37 | 62.91 | 60.66 | 10.07 | 5.07 | 1.18 | 35.05 | 0.1468 | 0.00 | 6.94 | 10.60 | 45.07 | -- | 16.32 | -- |
| Orion Oyj | 1.22bn | 216.80m | 5.06bn | 3.70k | 23.13 | 7.11 | 19.17 | 4.15 | 1.55 | 1.55 | 8.71 | 5.04 | 0.8866 | 1.57 | 6.01 | 336,013.20 | 15.73 | 19.47 | 21.38 | 24.16 | 55.10 | 59.38 | 17.74 | 20.71 | 1.00 | 74.43 | 0.2157 | 91.83 | -11.26 | 4.01 | -37.97 | 1.89 | 11.82 | 1.55 |
| Zealand Pharma A/S | 45.97m | -94.37m | 5.29bn | 253.00 | -- | 23.09 | -- | 115.14 | -12.57 | -12.57 | 6.01 | 27.28 | 0.1948 | 4.16 | 289.88 | 1,354,889.00 | -39.99 | -42.74 | -46.30 | -50.24 | 87.39 | 96.13 | -205.30 | -464.66 | 6.23 | -- | 0.0696 | -- | 229.65 | 55.27 | 27.12 | -- | 42.53 | -- |
| Swedish Orphan Biovitrum AB (publ) | 1.98bn | 182.99m | 8.64bn | 1.75k | 46.11 | 2.70 | 18.21 | 4.37 | 6.19 | 6.19 | 69.32 | 105.59 | 0.3603 | 1.50 | 4.72 | 13,058,130.00 | 3.33 | 5.93 | 4.43 | 7.60 | 76.60 | 77.42 | 9.25 | 16.61 | 0.4994 | 3.56 | 0.3487 | 0.00 | 17.74 | 19.34 | -8.68 | -0.0729 | 53.61 | -- |
| Genmab A/S | 2.21bn | 583.59m | 17.43bn | 2.20k | 29.76 | 4.06 | -- | 7.89 | 66.05 | 66.05 | 249.95 | 483.85 | 0.5037 | -- | 3.09 | 7,474,592.00 | 13.31 | 17.43 | 14.25 | 18.59 | 55.82 | -- | 26.42 | 35.87 | 13.32 | -- | 0.0238 | -- | 13.57 | 40.35 | -20.18 | 24.21 | -4.66 | -- |
Data as of May 02 2024. Currency figures normalised to Orion Oyj's reporting currency: Euro EUR
19.37%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 05 Apr 2024 | 3.77m | 3.49% |
| Keskin�inen Ty�el�kevakuutusyhti� Varmaas of 28 Feb 2023 | 3.18m | 2.95% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 2.78m | 2.57% |
| BlackRock Fund Advisorsas of 04 Apr 2024 | 2.59m | 2.40% |
| Keskin�inen El�kevakuutusyhti� Ilmarinenas of 21 Jun 2023 | 1.93m | 1.79% |
| Keskin�inen Ty�el�kevakuutusyhti� Eloas of 28 Feb 2023 | 1.59m | 1.48% |
| Dimensional Fund Advisors LPas of 04 Apr 2024 | 1.58m | 1.46% |
| The Social Insurance Institution of Finland (Invt Port)as of 28 Feb 2023 | 1.22m | 1.13% |
| Handelsbanken Fonder ABas of 31 Mar 2024 | 1.15m | 1.06% |
| Sp-Fund Management Co. Ltd.as of 28 Mar 2024 | 1.12m | 1.04% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
